Zi-long Wang

Beijing, 100044, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 26 publications

Macro-Aspartate Aminotransferase With Metabolic Dysfunction-Associated Fatty Liver Disease in Adults:Report of One Case.

Macro-Aspartate Aminotransferase With Metabolic Dysfunction-Associated Fatty Liver Disease in Adults:Report of One Case.

Journal: Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae

Published: January 08, 2026

Endothelial cells expressing CPE and vWF are involved in the Immunopathogenesis of primary biliary cholangitis.

Endothelial cells expressing CPE and vWF are involved in the Immunopathogenesis of primary biliary cholangitis.

Journal: Scientific reports

Published: April 06, 2025

Pyroptosis Plays a Key Role Through Macrophages in Primary Biliary Cholangitis of Mice.

Pyroptosis Plays a Key Role Through Macrophages in Primary Biliary Cholangitis of Mice.

Journal: BioMed research international

Published: March 27, 2025

Hepatic Steatosis Analysis in Metabolic Dysfunction-Associated Steatotic Liver Disease Based on Artificial Intelligence.

Hepatic Steatosis Analysis in Metabolic Dysfunction-Associated Steatotic Liver Disease Based on Artificial Intelligence.

Journal: Diagnostics (Basel, Switzerland)

Published: November 10, 2024

Exploring the Pathogenesis of Autoimmune Liver Diseases from the Heterogeneity of Target Cells.

Exploring the Pathogenesis of Autoimmune Liver Diseases from the Heterogeneity of Target Cells.

Journal: Journal of clinical and translational hepatology

Published: November 26, 2023

Incomplete response to ursodeoxycholic acid in primary biliary cholangitis: criteria, epidemiology, and possible mechanisms.

Incomplete response to ursodeoxycholic acid in primary biliary cholangitis: criteria, epidemiology, and possible mechanisms.

Journal: Expert review of gastroenterology & hepatology

Published: December 05, 2022

Treatment of ursodeoxycholic acid with glucocorticoids and immunosuppressants may improve the long-term survival rate in primary biliary cholangitis patients.

Treatment of ursodeoxycholic acid with glucocorticoids and immunosuppressants may improve the long-term survival rate in primary biliary cholangitis patients.

Journal: Medicine

Published: November 19, 2022

Hepatitis B functional cure and immune response.

Hepatitis B functional cure and immune response.

Journal: Frontiers in immunology

Published: October 21, 2022

Lower alanine aminotransferase levels are associated with increased all-cause and cardiovascular mortality in nonalcoholic fatty liver patients.

Lower alanine aminotransferase levels are associated with increased all-cause and cardiovascular mortality in nonalcoholic fatty liver patients.

Journal: World journal of hepatology

Published: October 19, 2022

An Ideal Hallmark Closest to Complete Cure of Chronic Hepatitis B Patients: High-sensitivity Quantitative HBsAg Loss.

An Ideal Hallmark Closest to Complete Cure of Chronic Hepatitis B Patients: High-sensitivity Quantitative HBsAg Loss.

Journal: Journal of clinical and translational hepatology

Published: June 11, 2022

Combination therapy of ursodeoxycholic acid and glucocorticoid and (or) immunosuppressant in patients with primary biliary cholangitis: A meta-analysis.

Combination therapy of ursodeoxycholic acid and glucocorticoid and (or) immunosuppressant in patients with primary biliary cholangitis: A meta-analysis.

Journal: Medicine

Published: November 03, 2021

Peripheral and central sites of action for anti-allodynic activity induced by the bifunctional opioid/NPFF receptors agonist BN-9 in inflammatory pain model.

Peripheral and central sites of action for anti-allodynic activity induced by the bifunctional opioid/NPFF receptors agonist BN-9 in inflammatory pain model.

Journal: European journal of pharmacology

Published: March 05, 2017

Showing 1-12 of 26

Last Updated: 09/26/2026